Loratadine Clinical Trials On General Hives Suggested By NDAC Members
This article was originally published in The Tan Sheet
Executive Summary
An OTC switch of Schering-Plough's non-sedating antihistamine Claritin for general hives would require data from an evidence-based study of acute urticaria, Jesse Joad, MD, UC-Davis Medical Center, asserted at a meeting of FDA's Nonprescription Drugs Advisory Committee April 22
You may also be interested in...
Schering OTC Claritin Post-Approval Filings To Include Hypospadia Reports
Schering-Plough's post-approval commitments for OTC Claritin include submitting to FDA reported cases of the birth defect hypospadia following maternal ingestion of loratadine, the company said
Schering OTC Claritin Post-Approval Filings To Include Hypospadia Reports
Schering-Plough's post-approval commitments for OTC Claritin include submitting to FDA reported cases of the birth defect hypospadia following maternal ingestion of loratadine, the company said
Claritin “Market Transition Period” Will Entail Rx Sales Post-OTC Approval
Schering-Plough plans to continue marketing Rx Claritin during a "transition period" following FDA approval of an OTC version of the allergy remedy